--- title: "新的質量措施揭示了阿片類藥物治療項目中醫療補助患者保留率的顯著差異" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/273552099.md" description: "RTI International 在 JAMA Network Open 上發佈的一項研究揭示了美國阿片類藥物治療項目（OTPs）中醫療補助患者保留率的顯著差異。研究表明，僅有 61% 的醫療補助患者在第一個月後繼續接受治療，而排名最低的 25% 的項目僅保留了 40% 的患者。該研究強調了治療保留作為阿片類藥物使用障礙患者康復和生存的預測指標的重要性。研究結果建議，OTPs 可以利用這些基準來識別患者參與度改善的領域" datetime: "2026-01-23T20:10:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273552099.md) - [en](https://longbridge.com/en/news/273552099.md) - [zh-HK](https://longbridge.com/zh-HK/news/273552099.md) --- # 新的質量措施揭示了阿片類藥物治療項目中醫療補助患者保留率的顯著差異 _RTI opioid treatment program-level measures of retention highlight opportunities for quality improvement_ RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 /PRNewswire/ -- A **new study** published in JAMA Network Open and authored by experts at RTI International, an independent scientific research institute, has found that many opioid treatment programs (OTPs) across the U.S. are struggling to keep patients engaged. According to the study, at typical opioid treatment programs, 61% of Medicaid patients remained in care beyond the first month, but, among the bottom quarter of programs, only 40% remained in treatment for at least one month. "For opioid use disorder, treatment retention is one of the strongest predictors of recovery and survival for patients experiencing opioid use disorder," said lead author **Tami Mark**, Ph.D., a Distinguished Fellow at RTI. "This new measure offers OTPs a consistent benchmark that shows how their retention rates align with national patterns, enabling programs to pinpoint strengths, isolate gaps and prioritize targeted improvements." RTI researchers created case-mix adjusted retention measures using Medicaid claims data from 2018 to 2023. In 2023, the measures included more than 1,100 OTPs, 432,000 treatment episodes, and 261,000 patients. The measures reveal a wide variation in OTPs' retention rates: - OTPs in the top 75% retained 73.5% of participants for 30 days, compared with 40.9% in the bottom 25%. - At 90 days, top OTPs retained 54.8%, while bottom–quartile programs retained 22.2%. - At 180 days, retention was 40.5% in the top group and 11.4% in the bottom group. RTI researchers **Dylan DeLisle**, MPH, Chelsea Katz, Ph.D.; **William Dowd**, Ph.D.; **Daniel Barch**, Ph.D.; Marianne Kluckman, MPH, also contributed to the study, which was supported by the **NIH HEAL Initiative**. **Read the full study** **Learn more about RTI's substance use research** **About RTI International** RTI International is an independent scientific research institute dedicated to improving the human condition. Our vision is to address the world's most critical problems with technical and science-based solutions in pursuit of a better future. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across social, statistical, data, and laboratory sciences, engineering, and other technical disciplines to solve the world's most challenging problems. For more information, visit **www.rti.org**. Media Contact: RTI International Media Relations 408153@email4pr.com 919-541-7300 View original content:https://www.prnewswire.com/news-releases/new-quality-measures-reveal-wide-variation-in-opioid-treatment-programs-medicaid-patient-retention-rates-302669211.html SOURCE RTI International ### 相關股票 - [CURE.US](https://longbridge.com/zh-HK/quote/CURE.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [IOVA.US](https://longbridge.com/zh-HK/quote/IOVA.US.md) - [RSPH.US](https://longbridge.com/zh-HK/quote/RSPH.US.md) - [ALKS.US](https://longbridge.com/zh-HK/quote/ALKS.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [ELV.US](https://longbridge.com/zh-HK/quote/ELV.US.md) - [MOH.US](https://longbridge.com/zh-HK/quote/MOH.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [PAHC.US](https://longbridge.com/zh-HK/quote/PAHC.US.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [CNC.US](https://longbridge.com/zh-HK/quote/CNC.US.md) - [HOOK.US](https://longbridge.com/zh-HK/quote/HOOK.US.md) - [RXL.US](https://longbridge.com/zh-HK/quote/RXL.US.md) - [UNH.US](https://longbridge.com/zh-HK/quote/UNH.US.md) - [ACHC.US](https://longbridge.com/zh-HK/quote/ACHC.US.md) - [CVS.US](https://longbridge.com/zh-HK/quote/CVS.US.md) - [UNHG.US](https://longbridge.com/zh-HK/quote/UNHG.US.md) - [XHS.US](https://longbridge.com/zh-HK/quote/XHS.US.md) - [IHF.US](https://longbridge.com/zh-HK/quote/IHF.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [INDV.US](https://longbridge.com/zh-HK/quote/INDV.US.md) ## 相關資訊與研究 - [Anthem Blue Cross 和 Blue Shield 與西奈山健康系統達成新的多年協議](https://longbridge.com/zh-HK/news/282626767.md) - [FDA 將考慮擴大肽類復配範圍](https://longbridge.com/zh-HK/news/283001654.md) - [巨生醫細胞治療產品獲 SelectUSA Tech 醫療領域前 8 強 有助美國市場佈局](https://longbridge.com/zh-HK/news/282988767.md) - [巨生醫細胞治療產品 MPB-2354 獲選 SelectUSA Tech 醫療領域前八強](https://longbridge.com/zh-HK/news/282972944.md) - [鉅亨速報 - Factset 最新調查：Summit Therapeutics Inc(SMMT-US) EPS 預估上修至-1.2 元，預估目標價為 33.00 元](https://longbridge.com/zh-HK/news/282998825.md)